Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

UPDATE 3-India, Brazil to take EU to court in generics row

Published 10/22/2009, 02:00 PM
Updated 10/22/2009, 01:27 PM

* India, Brazil decide on case against EU on generics

* No date for launching case

* Case triggered by Dutch seizure of blood pressure drug

* Drug was generic made in India en route for Brazil

(Adds EU comment)

By Jonathan Lynn

GENEVA, Oct 22 (Reuters) - India and Brazil will take the European Union to court at the World Trade Organisation, diplomats said on Thursday, raising the stakes in a bitter dispute over seizures of generic drugs.

WTO ambassadors from the two emerging powers told Reuters their governments had decided to request consultations with the EU in the row, the first step in launching a formal trade dispute.

Developing countries believe the case, originally involving the seizure by Dutch customs of a blood pressure drug en route from India to Brazil last December, is a symbol of their mistreatment by rich nations and corporations.

It also sums up a major dilemma in trade and intellectual property policy -- how to reconcile the provision of affordable medicine to people in poor countries with the need to encourage medical research through patent protection.

"We've taken the decision to launch consultations," India's WTO ambassador Ujal Singh Bhatia told Reuters. "We're just completing the procedural work."

"As of now the decision in Brasilia is to move forward," Brazil's WTO ambassador Roberto Azevedo said.

The two have not yet decided when to notify the request formally to the WTO, as they continue to prepare the case.

Sounding a conciliatory note, the European Commission said it took access to medicines for developing countries seriously and was examining the seizures of drugs last year.

"The Commission agrees that necessary action against counterfeit and dangerous medicines should not be at the expense of trade in genuine generic medicines," Lutz Guellner, spokesman for European Trade Commissioner Catherine Ashton, told Reuters.

Ashton had discussed the question with India's Commerce and Industry Minister Anand Sharma earlier this month and agreed to continue working on it, he said.

"DOUBLE STANDARDS"

In a report this week, campaign groups Oxfam and Health Action International accused Europe of double standards by cracking down on medicine prices at home while undermining access to cheap drugs in poor countries.

Since late 2008, Dutch and German officials have made customs seizures totalling 19 shipments of generic medicines bound for developing countries, Oxfam and HAI said.

Elise Ford, Oxfam head of EU advocacy, said the action would result in higher medicine prices in developing countries, just as the European Commission was stepping up its own campaign to ensure access to cheap generics within EU member states.

European antitrust regulators have launched a series of raids of pharmaceutical companies since January 2008 in a bid to uncover potentially illegal blocks on generics, which they suspect are pushing up costs for EU healthcare systems.

India and Brazil say last December's seizure, which has since been repeated, is part of a pattern by rich nations to claw back special treatment agreed for poor countries.

The EU says it has the right to inspect generic drugs in transit to protect its citizens and people in developing countries from fake medicines.

Last December's seizure involved a shipment of losartan, the generic name for Merck & Co's blood pressure drug Cozaar, which was developed jointly by Merck and E I du Pont de Nemours & Co.

The drugs had been exported by India's Dr Reddys Laboratories Ltd, which flew them back to India after customs released them.

Formally, under WTO rules, India and Brazil would launch separate complaints, although these could be consolidated into a single case.

"The legal teams are already talking to each other and getting ready," Azevedo said. "If there's a claim by one then the other has to make a claim that is consistent." (Additional reporting by Ben Hirschler in London)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.